upadacitinib
JAK Inhibitor Upadacitinib Approved for New Rheumatologic Condition
The indication is the drug's sixth, and fourth for rheumatologic disease.
OCTOBER 26, 2022
Upadacitinib Approved for Adults With Active Ankylosing Spondylitis
The FDA approved upadacitinib for the treatment of adults with active ankylosing spondylitis who have had an ...
MAY 4, 2022
Upadacitinib Receives FDA Approval for Active Psoriatic Arthritis
The FDA approved 15 mg of once-daily upadacitinib for the treatment of adults with active psoriatic arthritis who ...
DECEMBER 16, 2021
Load more